Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.
作者： James E. Butrynski , David R. D'Adamo , Jason L. Hornick , Paola Dal Cin , Cristina R. Antonescu
关键词: Cancer research 、 Inflammatory myofibroblastic tumour 、 Anaplastic lymphoma kinase 、 Medicine 、 Receptor 、 Myofibroblast 、 ALK inhibitor 、 Inflammation 、 Proto-Oncogene Proteins c-met 、 Crizotinib
摘要: Inflammatory myofibroblastic tumor (IMT) is a distinctive mesenchymal neoplasm characterized by spindle-cell proliferation with an inflammatory infiltrate. Approximately half of IMTs carry rearrangements the anaplastic lymphoma kinase (ALK) locus on chromosome 2p23, causing aberrant ALK expression. We report sustained partial response to inhibitor crizotinib (PF-02341066, Pfizer) in patient ALK-translocated IMT, as compared no observed activity another without translocation. These results support dependence ALK-rearranged tumors ALK-mediated signaling and suggest therapeutic strategy for genomically identified patients aggressive form this soft-tissue tumor. (Funded Pfizer others; ClinicalTrials.gov number, NCT00585195.).
cshl.edu
sci-hub.se 参考文章(24)
B C Gleason, J L Hornick, Inflammatory myofibroblastic tumours: where are we now? Journal of Clinical Pathology. ,vol. 61, pp. 428- 437 ,(2008) , 10.1136/JCP.2007.049387
J. G. Christensen, H. Y. Zou, M. E. Arango, Q. Li, J. H. Lee, S. R. McDonnell, S. Yamazaki, G. R. Alton, B. Mroczkowski, G. Los, Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma Molecular Cancer Therapeutics. ,vol. 6, pp. 3314- 3322 ,(2007) , 10.1158/1535-7163.MCT-07-0365
Michael C. Heinrich, Christopher L. Corless, George D. Demetri, Charles D. Blanke, Margaret von Mehren, Heikki Joensuu, Laura S. McGreevey, Chang-Jie Chen, Annick D. Van den Abbeele, Brian J. Druker, Beate Kiese, Burton Eisenberg, Peter J. Roberts, Samuel Singer, Christopher D.M. Fletcher, Sandra Silberman, Sasa Dimitrijevic, Jonathan A. Fletcher, Kinase Mutations and Imatinib Response in Patients With Metastatic Gastrointestinal Stromal Tumor Journal of Clinical Oncology. ,vol. 21, pp. 4342- 4349 ,(2003) , 10.1200/JCO.2003.04.190
Cheryl M. Coffin, Jan Watterson, John R. Priest, Louis P. Dehner, Extrapulmonary Inflammatory Myofibroblastic Tumor (Inflammatory Pseudotumor) A Clinicopathologic and Immunohistochemical Study of 84 Cases The American Journal of Surgical Pathology. ,vol. 19, pp. 859- 872 ,(1995) , 10.1097/00000478-199508000-00001
Tony S. Mok, Yi-Long Wu, Sumitra Thongprasert, Chih-Hsin Yang, Da-Tong Chu, Nagahiro Saijo, Patrapim Sunpaweravong, Baohui Han, Benjamin Margono, Yukito Ichinose, Yutaka Nishiwaki, Yuichiro Ohe, Jin-Ji Yang, Busyamas Chewaskulyong, Haiyi Jiang, Emma L. Duffield, Claire L. Watkins, Alison A. Armour, Masahiro Fukuoka, Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma The New England Journal of Medicine. ,vol. 361, pp. 947- 957 ,(2009) , 10.1056/NEJMOA0810699
E. L. Kwak, D. R. Camidge, J. Clark, G. I. Shapiro, R. G. Maki, M. J. Ratain, B. Solomon, Y. Bang, S. Ou, R. Salgia, Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066 Journal of Clinical Oncology. ,vol. 27, pp. 3509- 3509 ,(2009) , 10.1200/JCO.2009.27.15_SUPPL.3509
Marc Ladanyi, Aberrant ALK tyrosine kinase signaling. Different cellular lineages, common oncogenic mechanisms. American Journal of Pathology. ,vol. 157, pp. 341- 345 ,(2000) , 10.1016/S0002-9440(10)64545-2
Tara Ellingham, Elizabeth J. Perlman, Constance A. Griffin, Anita L. Hawkins, Cecily Dvorak, Carol Henkle, Recurrent Involvement of 2p23 in Inflammatory Myofibroblastic Tumors Cancer Research. ,vol. 59, pp. 2776- 2780 ,(1999)
Ruth H. Palmer, Emma Vernersson, Caroline Grabbe, Bengt Hallberg, Anaplastic lymphoma kinase: signalling in development and disease Biochemical Journal. ,vol. 420, pp. 345- 361 ,(2009) , 10.1042/BJ20090387
Sylvie Giuriato, Nathalie Faumont, Emilie Bousquet, Marianne Foisseau, Anne Bibonne, Marc Moreau, Talal Al Saati, Dean Felsher, Georges Delsol, Fabienne Meggetto, Development of a conditional bioluminescent transplant model for TPM3-ALK-induced tumorigenesis as a tool to validate ALK-dependent cancer targeted therapy. Cancer Biology & Therapy. ,vol. 6, pp. 1318- ,(2007) , 10.4161/CBT.6.8.4508